Clinical trials: Mental Depression
Major Depressive Disorder
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response…
- Trial name
- NCT06633016
- Testing
- ABX-002
- Where
- 50 sites in United States
- Volunteers
- 230 people
- Sponsor
- Autobahn Therapeutics, Inc.
Mild Cognitive Impairment, Anxiety State
Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI
This Phase I/II clinical trial aims to test the effectiveness of a new sublingual formulation of 5-MeO-DMT in reducing symptoms of anxiety, depression, and cognitive decline in individuals with mild to moderate Alzheimer's…
- Conditions
- Mild Cognitive Impairment, Anxiety State, Depression Anxiety Disorder
- Trial name
- 5-MeO-DMT (NCT06812221)
- Testing
- Sublingual administration, Electroencephalography, Biochemical mesurements
- Where
- Argentina
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Biomind Labs Inc.
Generalized Anxiety Disorder
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)
The purpose of this proof-of-concept trial is to examine the safety, tolerability, and pharmacokinetics (PK), and preliminary clinical efficacy of CYB004 participants with GAD.
- Trial name
- NCT06051721
- Testing
- CYB004, Psychotherapy
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- Cybin IRL Limited
Multiple Myeloma
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form…
- Trial name
- NCT02921828
- Where
- 2 sites in United States, Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Major Depressive Disorder
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression
The purposes of this study are to determine: Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression.
- Trial name
- NCT00035321
- Testing
- Olanzapine, Fluoxetine
- Where
- 33 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
A Study to Test Different Doses of BI 1569912 in People With Depression
This study is open to adults between 18 and 65 years of age with a type of depression called major depressive disorder. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression.
- Trial name
- NCT06558344
- Testing
- 5 mg BI 1569912, 10 mg BI 1569912, 20 mg of BI 1569912
- Where
- 41 sites in United States, Japan
- Volunteers
- 225 people
- Sponsor
- Boehringer Ingelheim
Major Depression, Dysthymia
Implementation of Harmonized Depression Outcome Measures in a Health System
Working with a health system, the investigators will recruit practices to participate in the pilot study, consent and enroll patients with major depressive disorder, and collect the PHQ-9 from those patients at three timepoints…
- Trial name
- NCT04235712
- Testing
- Harmonized Depression Outcome Measures
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- OM1, Inc.
Major Depressive Disorder
Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders
The purpose of this study is to demonstrate superior efficacy of Quetiapine fumarate sustained release (SEROQUEL) compared with placebo when used as a mono-therapy in the treatment of Major Depressive Disorders PLEASE NOTE…
- Trial name
- OPAL (NCT00326144)
- Testing
- Quetiapine fumarate
- Where
- 34 sites in United States
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Treatment Resistant Depression
Virtual Neuro-Navigation System for Personalized Community Based TMS
Phase I study of a virtual neuro-navigation package with built-in support for identifying specific "surface-based" targets to optimze TMS treatment.
- Trial name
- NCT04956081
- Testing
- Neuro-navigated Transcranial Magnetic Stimulation (TMS)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Soterix Medical
Bipolar Depression
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression
- Trial name
- NCT00868699
- Testing
- lurasidone
- Where
- 55 sites in United States, Czechia and 6 more
- Volunteers
- 505 people
- Sponsor
- Sumitomo Pharma America, Inc.
Depressive Disorder, Depression
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who…
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- Polaris (NCT01360632)
- Testing
- OPC-34712 + ADT
- Where
- 71 sites in United States, Canada and 5 more
- Volunteers
- 1,539 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Unipolar Depression, Major Depressive Disorder (MDD)
Validation of EmoDTx as a Digital Endpoint for Mood Monitoring in Adult Patients Suffering From Unipolar Depression
The aim of this study is to validate the EmoDTx as a digital tool for mood monitoring in adult patients with unipolar depression. The study is prospective, multicenter, and observational, with a single-arm approach.
- Conditions
- Unipolar Depression, Major Depressive Disorder (MDD), Depression
- Trial name
- EMC2FR (NCT06860165)
- Where
- 2 sites in France
- Volunteers
- 98 people
- Sponsor
- Emobot
Major Depressive Disorder
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)
The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).
- Trial name
- NCT06423781
- Testing
- BHV-7000
- Where
- 66 sites in United States
- Volunteers
- 233 people
- Sponsor
- Biohaven Therapeutics Ltd.
Anxiety, Fear
An Exploratory Investigation of a CBD Supplement's Impact on Sleep, Stress, and Focus
A high-quality broad-spectrum cannabidiol supplement with a bio-terpene complex will be administered once daily. It is hypothesized that this supplement will lead to improvements in sleep, focus, and stress.
- Conditions
- Anxiety, Fear, Stress, Low Mood
- Trial name
- NCT05518019
- Testing
- The Daily Supplement
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Prima CBD
Depressive Disorder, Major
A Study to Evaluate the Effect of Food on LY2216684
This study will evaluate the effect of food on LY2216684. There will be 2 study periods each lasting up to 5 days. There will be at least 7 days between the two doses and a follow up will occur at least 7 days after the last…
- Trial name
- NCT01389765
- Testing
- LY2216684
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine
The purpose of the study is to describe the association/correlation between change in patient-reported cognitive symptoms and work productivity in gainfully employed patients receiving vortioxetine for a Major Depressive Episode…
- Trial name
- AtWoRC (NCT02332954)
- Testing
- vortioxetine
- Where
- 26 sites in Canada
- Volunteers
- 226 people
- Sponsor
- Lundbeck Canada Inc.
Depressive Disorder, Major
Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)
Multicenter, open-label, long-term extended access treatment protocol in adult patients with a primary diagnosis of MDD.
- Trial name
- NCT03668600
- Testing
- Rapastinel
- Where
- 74 sites in United States
- Volunteers
- 230 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder
Duloxetine Versus Paroxetine for Major Depression
To determine if duloxetine works just as well as paroxetine in the treatment of major depressive disorder.
- Trial name
- NCT00489775
- Testing
- Duloxetine, Paroxetine
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Eli Lilly and Company
Bipolar Depression
A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression
The main goal of this study is to help answer the following research question(s) and not to treat the child's illness. Can this study drug make children with bipolar depression feel better? Does this study drug work better than a…
- Trial name
- NCT00844857
- Testing
- Olanzapine Fluoxetine Combination (OFC)
- Where
- 7 sites in United States, Russia
- Volunteers
- 291 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
A Prospective Epidemiological Research on Functioning Outcomes Related to Major Depressive Disorder
The purpose of this study is to describe patient functioning and examine associations between depressive symptoms and measures of the various roles of functioning.
- Trial name
- PERFORM (NCT01427439)
- Where
- France
- Volunteers
- 1,455 people
- Sponsor
- H. Lundbeck A/S